{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000002","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.464965+00:00","generated_at":"2026-05-16T10:56:50.817478+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"AEON Biopharma issues corporate presentation with no new material facts","bullets":["Presentation dated January 2026 made available on IR website (Item 7.01).","Reiterates ABP-450 as biosimilar to BOTOX, aiming to be first complete therapeutic alternative.","No financial or clinical data disclosed; no guidance or milestones provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000002","json":"https://secwatch.observer/filing/0001837607-26-000002.json","markdown":"https://secwatch.observer/filing/0001837607-26-000002.md","text":"https://secwatch.observer/filing/0001837607-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/0001837607-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/aeon-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:56:50.817478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}